Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video) - 2Astronauts beam home Christmas wishes from International Space Station: 'I think we may be orbiting a little higher than Santa' (video)
- 3Keep It Cool: Uncovering Famous Fridge Brands for Each Home
- 4Understanding Successful Compromise Standards to Cultivate Agreeable Connections
- 5‘This year nearly broke me as a scientist’ – US researchers reflect on how 2025’s science cuts have changed their lives
- Recent studies prove the ancient practice of nasal irrigation is effective at fighting the common cold
- Magnetic fossils may reveal ancient creature's internal 'GPS system'
- Washington resident is infected with a different type of bird flu
- Doritos and Cheetos debut 'NKD' options, without artificial colors or flavors
- How to see the Ursids, the final meteor shower of 2025
- Here's how 'Bridgerton' fans can watch the first episode of Season 4 before its Netflix release later this month
- Find the Marvels of the World with These Travels
- Manual for Vegetarian Protein Powder
- Israel faces tough choices over haredi draft exemptions, legal expert warns
